

CLAIM AMENDMENTS

This listing of claims will replace all previous listing of claims.

Listing of Claims:

1.-55. Cancelled

56. (New) A method for determining whether a subject is afflicted with cancer, comprising determining whether OX-2/CD200 is upregulated in said subject.

57. (New) The method of claim 56, wherein upregulation of OX-2/CD200 in said subject is determined using an antibody, or antigen binding fragment thereof, that specifically binds to OX-2/CD200.

58. (New) The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, Fv, scFv, Fab' and F(ab')₂.

59. (New) The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, is humanized or human.

60. (New) The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 12, a light chain CDR2 having the sequence set forth in SEQ ID NO: 23, a light chain CDR3 having the sequence set forth in SEQ ID NO: 37, a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 55, a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 74, and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 93.

61. (New) The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 5; a light chain CDR2 having the sequence set forth in SEQ ID NO: 21; a light chain CDR3 having the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 88.
62. (New) The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 13; a light chain CDR2 having the sequence set forth in SEQ ID NO: 23; a light chain CDR3 having the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 94.
63. (New) The method of claim 56, wherein the cancer is chronic lymphocytic leukemia (CLL).
64. (New) The method of claim 56, wherein the cancer is melanoma.
65. (New) The method of claim 56, wherein the method further comprises administering to those subjects afflicted with cancer, an antibody, or antigen binding fragment thereof, that specifically binds to OX-2/CD200.
66. (New) The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, Fv, scFv, Fab' and F(ab')₂.
67. (New) The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, is humanized or human.

68. (New) The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 12, a light chain CDR2 having the sequence set forth in SEQ ID NO: 23, a light chain CDR3 having the sequence set forth in SEQ ID NO: 37, a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 55, a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 74, and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 93.

69. (New) The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 5; a light chain CDR2 having the sequence set forth in SEQ ID NO: 21; a light chain CDR3 having the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 88.

70. (New) The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 13; a light chain CDR2 having the sequence set forth in SEQ ID NO: 23; a light chain CDR3 having the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 94.